In terms of salvage therapies, the three arms were essentially the same with respect to the time to first subsequent therapy post progression and the time to first life-prolonging therapy. And among the patients receiving life-prolonging therapies, there was similar exposure to various agents, such as docetaxel and abiraterone.
Dr. James and Dr. Sartor disclosed that they receive honoraria and/or have consulting or advisory roles with numerous pharmaceutical companies.